(Tromsø, 1 March 2018) Biotec Pharmacon ASA's ("Biotec", OSE: BIOTEC) subsidiary
Biotec BetaGlucans has evaluated data from a 300 patient study, showing
significantly improved outcome for wounds using Woulgan® Gel compared to
standard care.
Biotec BetaGlucans has received complete data sets from the 300-patient study
where Woulgan® Gel was used for treating various types of stalled wounds. During
12-weeks, 150 patients were treated with Woulgan® Gel and 150 patients were
treated with standard care. The study included typical chronic wounds such as
diabetic foot ulcers, venous leg ulcers, arterial leg ulcers and pressure ulcers
(N=76), as well as more acute wounds such as burns, surgical wounds, donor sites
and a variety of trauma wounds (N=74). All wounds included were considered
stalled, having shown less than 40% reduction in size during the 4 weeks prior
to treatment.
The study showed that Woulgan® Gel significantly increases the likelihood of
wound healing compared to standard wound care (p <0.01) for stalled wounds of
all types. The most significant effect of Woulgan® Gel was seen in chronic
wounds where over 60% of the wounds healed within a 12-week period compared to
about 30% for standard care. Woulgan also had a striking effect in patients with
more acute wounds such as burns and surgical wounds, where time to heal was
reduced by more than one week compared to standard care. In the group who had
pure trauma wounds (cuts, bites and skin lesions from, for example, traffic
accidents), there was almost 100% healing in both groups in the first 6 weeks,
with a slightly shorter average healing time in the group treated with Woulgan
(less than 4 weeks) compared to standard care (just over 4 weeks).
The study confirms that Woulgan® Gel can have a dramatically positive effect for
patients with stalled wounds compared to standard wound care. Stalled wounds
require long treatment periods and are very costly to treat. Based on this
study, Woulgan® Gel is shown to have a significant health and social economic
benefit which is crucial for every successful innovation in the market.
"We know that Woulgan has powerful documentation from multiple case series and
documented case stories, but this extensive UK study shows Woulgan's
effectiveness on an even larger population of diverse stalled wounds. We will
now use this data in our marketing efforts to persuade more clinicians to adopt
Woulgan into their local practice." says Biotec Pharmacon's CEO Christian
Jørgensen
For more information, please contact:
CEO Christian Jørgensen, tel +47 47 79 24 57
About Biotec BetaGlucans AS:
Biotec BetaGlucans is a wholly owned subsidiary of Biotec Pharmacon ASA. Biotec
BetaGlucans develops and manufactures novel immunomodulating products for
business areas including Woulgan®, a premium priced product in the advanced
wound care market, animal feed, consumer health, cosmetics, medical devices and
pharmaceuticals.
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. ArcticZymes develops, produces and markets enzymes of marine
origin used in molecular DNA technologies and diagnostics, representing growth
markets where rapid technological developments are creating a strong demand for
new and improved enzymes.